EA201891377A1 - ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ - Google Patents

ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ

Info

Publication number
EA201891377A1
EA201891377A1 EA201891377A EA201891377A EA201891377A1 EA 201891377 A1 EA201891377 A1 EA 201891377A1 EA 201891377 A EA201891377 A EA 201891377A EA 201891377 A EA201891377 A EA 201891377A EA 201891377 A1 EA201891377 A1 EA 201891377A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
channel modulators
pain treatment
treatment
pain
Prior art date
Application number
EA201891377A
Other languages
English (en)
Other versions
EA038059B1 (ru
Inventor
Чарльз Лардж
Джузеппе Альваро
Original Assignee
Отифони Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Отифони Терапьютикс Лимитед filed Critical Отифони Терапьютикс Лимитед
Publication of EA201891377A1 publication Critical patent/EA201891377A1/ru
Publication of EA038059B1 publication Critical patent/EA038059B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

Настоящее изобретение относится к модулятору каналов Kv3.1, и/или Kv3.2, и/или Kv3.3 для применения при профилактике или лечении боли. Модуляторы для применения при профилактике или лечении боли включают соединения формулы (I) или их фармацевтически приемлемые соли и/или сольваты и/или их производные:
EA201891377A 2015-12-10 2016-12-09 Применение модуляторов каналов kv3.1/kv3.2/kv3.3 для лечения боли EA038059B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses
PCT/GB2016/053879 WO2017098254A1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain

Publications (2)

Publication Number Publication Date
EA201891377A1 true EA201891377A1 (ru) 2019-01-31
EA038059B1 EA038059B1 (ru) 2021-06-30

Family

ID=55274489

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891377A EA038059B1 (ru) 2015-12-10 2016-12-09 Применение модуляторов каналов kv3.1/kv3.2/kv3.3 для лечения боли

Country Status (16)

Country Link
US (2) US11147813B2 (ru)
EP (1) EP3386506B1 (ru)
JP (2) JP7149847B2 (ru)
KR (1) KR20180097549A (ru)
AU (1) AU2016367239B2 (ru)
BR (1) BR112018011700B1 (ru)
CA (1) CA3005302A1 (ru)
DK (1) DK3386506T3 (ru)
EA (1) EA038059B1 (ru)
FI (1) FI3386506T3 (ru)
GB (1) GB201521751D0 (ru)
IL (1) IL259717B (ru)
MX (1) MX2018007074A (ru)
PT (1) PT3386506T (ru)
SG (1) SG11201804123VA (ru)
WO (1) WO2017098254A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018109484A1 (en) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
TWI827706B (zh) * 2018-10-16 2024-01-01 英商奧堤凡尼治療股份有限公司 新穎化合物
AR116898A1 (es) * 2018-10-30 2021-06-23 H Lundbeck As DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3
AU2020427632A1 (en) 2020-02-06 2022-08-18 Autifony Therapeutics Limited Kv3 modulators
KR20240046748A (ko) 2021-08-10 2024-04-09 오티포니 세라피틱스 리미티드 칼륨 채널 조절제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723626A1 (en) 2008-06-06 2009-12-10 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
CA2781685C (en) 2009-12-11 2018-09-04 Autifony Therapeutics Limited Imidazolidinedione derivatives
US9346790B2 (en) * 2010-12-06 2016-05-24 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
WO2012168710A1 (en) 2011-06-07 2012-12-13 Autifony Therapeutics Limited Hydantoin derivates as kv3 inhibitors
ES2576628T3 (es) * 2011-12-06 2016-07-08 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
JP6240667B2 (ja) 2012-05-22 2017-11-29 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのトリアゾール
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
IL259717A (en) 2018-07-31
BR112018011700B1 (pt) 2023-12-26
JP2019506367A (ja) 2019-03-07
KR20180097549A (ko) 2018-08-31
JP2022141699A (ja) 2022-09-29
IL259717B (en) 2021-05-31
BR112018011700A2 (pt) 2018-11-27
EP3386506B1 (en) 2024-01-24
FI3386506T3 (fi) 2024-04-23
JP7149847B2 (ja) 2022-10-07
SG11201804123VA (en) 2018-06-28
CN108472288A (zh) 2018-08-31
CA3005302A1 (en) 2017-06-15
US20190000848A1 (en) 2019-01-03
AU2016367239A1 (en) 2018-06-07
DK3386506T3 (da) 2024-05-06
GB201521751D0 (en) 2016-01-27
WO2017098254A1 (en) 2017-06-15
EA038059B1 (ru) 2021-06-30
AU2016367239B2 (en) 2020-07-09
US11147813B2 (en) 2021-10-19
US11944623B2 (en) 2024-04-02
PT3386506T (pt) 2024-03-28
EP3386506A1 (en) 2018-10-17
US20220071998A1 (en) 2022-03-10
MX2018007074A (es) 2018-12-12

Similar Documents

Publication Publication Date Title
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
PH12019501097A1 (en) Magl inhibitors
PH12019501102A1 (en) Magl inhibitors
PH12020551934A1 (en) Magl inhibitors
PH12019502646A1 (en) Pyrazole magl inhibitors
MX2018004664A (es) Antagonistas de ep4.
PH12016502353A1 (en) Pharmaceutical composition
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201991898A1 (ru) Двойные ингибиторы magl и faah
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA202090681A1 (ru) Модуляторы каналов crac для лечения рака пищевода
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
EA202190626A3 (ru) Комбинация тразодона и габапентина для лечения боли
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
EA202090803A1 (ru) Фармацевтическая композиция адапалена и миноциклина для наружного применения